AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1564581 — intervention group
Group type: COMPARATOR
Intervention: Lecture group (control)
Number of subjects: 80
Study 1564581 — intervention group
Group type: EXPERIMENTAL
Intervention: OH-CBL
Number of subjects: 80
Study 3925656 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg nitroglycerin ointment 2%
Number of subjects: 22
Study 3925656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31562872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral push-off skater exercise
Number of subjects: 36
Study 31562872 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill training
Number of subjects: 36
Study 30215593 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone alone (group 2)
Number of subjects: 99
Study 30215593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with hydromorphone (group 3)
Number of subjects: 99
Study 30215593 — intervention group
Group type: COMPARATOR
Intervention: Epidural placebo (group 1)
Number of subjects: 99
Study 28073199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 2.5% lidocaine and 2.5% prilocaine (Group A)
Number of subjects: 150
Study 28073199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthetic administration (lidocaine 5 ml 10%) and lidocaine local spray 15% (Group B)
Number of subjects: 150
Study 28073199 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic block anesthesia (lidocaine 10 ml 10%) (Group C)
Number of subjects: 150
Study 24359138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intraligamentary injection + buccal infiltration + IANB
Number of subjects: 82
Study 24359138 — intervention group
Group type: COMPARATOR
Intervention: Traditional IANB injection
Number of subjects: 82
Study 22549666 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided surgery with semicircular miniflap technique
Number of subjects: 24
Study 22549666 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 24
Study 20332351 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily liraglutide (1.8 mg)
Number of subjects: 0
Study 20332351 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing liraglutide
Number of subjects: 0
Study 20332351 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily exenatide (10 microg)
Number of subjects: 0
Study 18334461 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing (OHD; Karayahesive)
Number of subjects: 134
Study 18334461 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing (GD)
Number of subjects: 134
Study 15716701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20
Study 15716701 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma of nebivolol-treated patients
Number of subjects: 20
Study 15716701 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 20
Study 12105827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterologist-administered propofol
Number of subjects: 75
Study 12105827 — intervention group
Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 75
Study 10432168 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (150 mg t.i.d.)
Number of subjects: 127
Study 10432168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 10432168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 8523379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 27
Study 8523379 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day)
Number of subjects: 27
Study 2301902 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope limb blood flow measurement
Number of subjects: 25
Study 6458582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13
Study 6458582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13
Study 6458582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg body weight 13‐cis‐retinoic acid
Number of subjects: 13
Study 6458582 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid
Number of subjects: 13
Study 31926152 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU fortnightly for 12 weeks)
Number of subjects: 120
Study 31926152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30382728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 67
Study 30382728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 27903087 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day cervical preparation with osmotic dilator and misoprostol
Number of subjects: 70
Study 27903087 — intervention group
Group type: COMPARATOR
Intervention: Overnight cervical preparation with osmotic dilator and misoprostol
Number of subjects: 70
Study 25745875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg
Number of subjects: 122
Study 25745875 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 122
Study 25745875 — intervention group
Group type: COMPARATOR
Intervention: Sham/intravitreal aflibercept
Number of subjects: 122
Study 25745875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 122
Study 25745875 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept and Sham
Number of subjects: 122
Study 23342996 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP142 vaccine (50 μg) administered intramuscularly with adjuvant system AS01
Number of subjects: 56
Study 23342996 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 56
Study 21696307 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group)
Number of subjects: 1088
Study 21696307 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir with peginterferon-ribavirin for 8 weeks and placebo with peginterferon-ribavirin for 4 weeks (T8PR group)
Number of subjects: 1088
Study 21696307 — intervention group
Group type: COMPARATOR
Intervention: Placebo with peginterferon-ribavirin for 12 weeks (PR group)
Number of subjects: 1088
Study 19232112 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1500
Study 19232112 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1500
Study 17854661 — intervention group
Group type: EXPERIMENTAL
Intervention: APC I1307K allele in colorectal cancer patients (n=56)
Number of subjects: 113
Study 17854661 — intervention group
Group type: EXPERIMENTAL
Intervention: APC I1307K allele in stomach cancer patients (n=57)
Number of subjects: 113
Study 17854661 — intervention group
Group type: EXPERIMENTAL
Intervention: APC I1307K carriers
Number of subjects: 113
Study 17854661 — intervention group
Group type: COMPARATOR
Intervention: APC I1307K allele
Number of subjects: 113
Study 15078748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX), 180 mg
Number of subjects: 18
Study 15078748 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (ML), 10 mg
Number of subjects: 18
Study 15078748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 11346140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and metronidazole
Number of subjects: 221
Study 11346140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and amoxycillin
Number of subjects: 221
Study 11346140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and metronidazole (per protocol)
Number of subjects: 221
Study 11346140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, clarithromycin, and amoxycillin (per protocol)
Number of subjects: 221
Study 9588608 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (five 45‐min walking sessions/wk at 60‐75% maximum heart rate)
Number of subjects: 91
Study 9588608 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate energy restriction (4.19‐5.44 MJ or 1,200‐1,300 kcal x d(‐1))
Number of subjects: 91
Study 9588608 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet (combined intervention)
Number of subjects: 91
Study 9588608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise, no diet)
Number of subjects: 91
Study 7506013 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (0.5 to 2.0 ng/kg per min)
Number of subjects: 131
Study 7506013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 7506013 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 131
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-interferon (100 micrograms/m2 3x/week for 4 h i.v. every other week)
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-interferon (500 micrograms/m2 5x/week for 24 h i.v. every other week)
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon (18 x 10(6) U 3x/week weekly i.m.)
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon in combination with vinblastine (0.1 mg/kg every third week i.v.)
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-interferon
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon
Number of subjects: 0
Study 3141856 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with objective tumor response
Number of subjects: 0
Study 30342969 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-sharing agreement
Number of subjects: 247
Study 30342969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study 27803118 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 0
Study 27803118 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 0
Study 27803118 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle
Number of subjects: 0
Study 27803118 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline comparison)
Number of subjects: 0
Study 27803118 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (treatment failure comparison)
Number of subjects: 0
Study 27803118 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (temporal changes)
Number of subjects: 0
Study 26141467 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mL 10% tPA
Number of subjects: 62
Study 26141467 — intervention group
Group type: COMPARATOR
Intervention: 13 mL normal saline
Number of subjects: 62
Study 26141467 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 62
Study 23088627 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 80
Study 23088627 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot SP
Number of subjects: 80
Study 23088627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 80
Study 23088627 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80
Study 20506261 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 6059
Study 20506261 — intervention group
Group type: EXPERIMENTAL
Intervention: All NSAIDs
Number of subjects: 6059
Study 20506261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6059
Study 20506261 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 6059
Study 20506261 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, NSAID, and paracetamol use
Number of subjects: 6059
Study 19076728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and BH(4)
Number of subjects: 8
Study 19076728 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 8
Study 19076728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16399293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 511
Study 15527634 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri‐Strips Dry (Group A, n=50)
Number of subjects: 98
Study 15527634 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B, n=48)
Number of subjects: 98
Study 11442216 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimonate (20 mg Sb/kg/day) for 10 days
Number of subjects: 82
Study 11442216 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimonate (20 mg Sb/kg/day) for 20 days
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Children < 5 years in 10-day group
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Children < 5 years in 20-day group
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 5-14 years in 10-day group
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 5-14 years in 20-day group
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 15 years or more in 10-day group
Number of subjects: 82
Study 11442216 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 15 years or more in 20-day group
Number of subjects: 82
Study 10351142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus prednisone (n=13; 10 with albumin, 3 with FFP)
Number of subjects: 23
Study 10351142 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (n=10)
Number of subjects: 23
Study 10351142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 23
Study 8061763 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pen for growth hormone administration (Nordiject)
Number of subjects: 0
Study 8061763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% benzyl alcohol solvent
Number of subjects: 0
Study 8061763 — intervention group
Group type: EXPERIMENTAL
Intervention: 30G needle
Number of subjects: 0
Study 8061763 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic needle insertion device
Number of subjects: 0
Study 8061763 — intervention group
Group type: COMPARATOR
Intervention: Manual needle insertion device
Number of subjects: 0
Study 2853731 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg/day) for 4 weeks
Number of subjects: 15
Study 2853731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29474546 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly intervention messages, plus texted primary care appointment reminders and a monthly text message requesting confirmation of study participation
Number of subjects: 230
Study 29474546 — intervention group
Group type: COMPARATOR
Intervention: Texted reminders and monthly messages alone
Number of subjects: 230
Study 29474546 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly intervention messages
Number of subjects: 230
Study 28447460 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine supplementation
Number of subjects: 69
Study 28447460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24856961 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized CTZ microspheres
Number of subjects: 0
Study 24856961 — intervention group
Group type: COMPARATOR
Intervention: Marketed CTZ product
Number of subjects: 0
Study 24524605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 39
Study 24524605 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 21691166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-balloon catheter
Number of subjects: 293
Study 21691166 — intervention group
Group type: COMPARATOR
Intervention: Double-balloon catheter
Number of subjects: 293
Study 18475164 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9131
Study 12601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of medial frontal lesions involving the supplementary motor area (SMA)
Number of subjects: 12
Study 12601097 — intervention group
Group type: COMPARATOR
Intervention: Preoperative fMRI assessment
Number of subjects: 12
Study 12601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection involving SMA
Number of subjects: 12
Study 9857618 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA test for detection of antibodies against pertussis toxin
Number of subjects: 127
Study 9857618 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive haemagglutination test with B. pertussis endotoxin
Number of subjects: 127
Study 9857618 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without respiratory infections)
Number of subjects: 127
Study 7634134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse with 0.2% chlorhexidine (CHX) and 0.3% triclosan in soya oil, used twice daily for 4 days
Number of subjects: 0
Study 7634134 — intervention group
Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 0
Study 7634134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse with aqueous phase containing chlorhexidine combined with oily phase without triclosan
Number of subjects: 0
Study 7634134 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase mouthrinse with soya oil containing 0.3% triclosan
Number of subjects: 0
Study 7634134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CHX alone in water
Number of subjects: 0
Study 7634134 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya oil without triclosan
Number of subjects: 0
Study 2677081 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 24
Study 2677081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 148936 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 1)
Number of subjects: 10
Study 148936 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 2)
Number of subjects: 10
Study 148936 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin concentration higher than 14 micromol/l on day 5
Number of subjects: 10
Study 30603800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS to unaffected hemisphere
Number of subjects: 28
Study 30603800 — intervention group
Group type: COMPARATOR
Intervention: Conventional dysphagia rehabilitation
Number of subjects: 28
Study 28265014 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC), 4 cycles within 24 hours of ictus
Number of subjects: 26
Study 28265014 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 26
Study 25822861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel hypotonic super-ORS containing zinc (group 2)
Number of subjects: 83
Study 25822861 — intervention group
Group type: COMPARATOR
Intervention: Standard hypotonic ORS (group 1)
Number of subjects: 83
Study 23799163 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinophototherapy with topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day, applied twice a week for three weeks.
Number of subjects: 65
Study 23799163 — intervention group
Group type: COMPARATOR
Intervention: Topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day (Control group).
Number of subjects: 65
Study 21075562 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 416
Study 21075562 — intervention group
Group type: COMPARATOR
Intervention: Standard practice classroom-delivered Drug Awareness intervention
Number of subjects: 416
Study 19996663 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural/general anesthesia (0.5% bupivacaine with sevoflurane)
Number of subjects: 54
Study 19996663 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (sevoflurane and intravenous fentanyl)
Number of subjects: 54
Study 17299473 — intervention group
Group type: COMPARATOR
Intervention: LFD
Number of subjects: 39
Study 17299473 — intervention group
Group type: EXPERIMENTAL
Intervention: LCKD
Number of subjects: 39
Study 15303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 360
Study 15303633 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 7 days
Number of subjects: 360
Study 15303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 360
Study 15303633 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 360
Study 11344347 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide (withdrawal group)
Number of subjects: 33
Study 11344347 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (reference group)
Number of subjects: 33
Study 9484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od
Number of subjects: 656
Study 9484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 600 mg od
Number of subjects: 656
Study 9484875 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg tds
Number of subjects: 656
Study 7910229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg initial dose, then 10 mg daily)
Number of subjects: 18934
Study 7910229 — intervention group
Group type: COMPARATOR
Intervention: Transdermal glyceryl trinitrate (GTN, 10 mg daily after intravenous for the first 24 hours)
Number of subjects: 18934
Study 7910229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of lisinopril and GTN
Number of subjects: 18934
Study 29562612 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nutritional and dietary intervention including vitamin/mineral supplements, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and a healthy gluten‐free, casein‐free, soy‐free (HGCSF) diet
Number of subjects: 67